FIXED FIVE-YEAR COHORT AUDIT
近五年文献重新检索与对照
旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1
四个独立队列
数字为批次中保存的原始 PMID 数,不会随着日常监测改变。
集合关系
交集和差集均按 PMID 精确计算;DOI 只用于明细核对。
严格查询未命中、但影子组经 v3 筛选后合格
166 篇
KM 证据
仅检查 v3 元数据合格论文,不运行曲线数字化。
论文明细
共 4707 篇;可组合筛选集合关系、入排结果和 KM 证据。
| 论文 | 队列 | 集合关系 | v3 入排 | KM 证据 |
|---|---|---|---|---|
| Integration of New Systemic Adjuvant Therapies for Non-small Cell Lung Cancer: Role of the Surgeon. PMID 36174774 · Ann Thorac Surg · 2023-Jun 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer. PMID 36167599 · Eur Urol · 2023-Jun This is a Phase II randomized trial of a drug intervention in oncology, but it is excluded because the primary endpoint is a pathological response measure (minimal residual disease), not a time-to-event efficacy endpoint. The trial does not report OS, PFS, DFS, EFS, RFS, TTP, or any Kaplan-Meier or hazard ratio analysis. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Advancements of ALK inhibition of non-small cell lung cancer: a literature review. PMID 37577315 · Transl Lung Cancer Res · 2023-Jul-31 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Updates of perioperative multidisciplinary treatment for surgically resectable esophageal cancer. PMID 37282626 · Jpn J Clin Oncol · 2023-Jul-31 The record is a review/update article discussing multiple clinical trials and their results in a narrative format. While it mentions trials that are Phase III and randomized, it does not present original, formal results (e.g., survival curves, hazard ratios) for a single, specific trial. The publication type 'Clinical Trial, Phase III' is likely a general tagging for the topic, not an indicator that this specific article is a primary results report. |
H
L
S
B
|
旧组与严格 v3 交集 | needs_reviewmodel_uncertain | pending 0 Figure · 0 Panel · risk - |
| Hypofractionated stereotactic radiotherapy (HFSRT) versus single fraction stereotactic radiosurgery (SRS) to the resection cavity of brain metastases after surgical resection (SATURNUS): study protocol for a randomized phase III trial. PMID 37516835 · BMC Cancer · 2023-Jul-29 方案论文未报告临床试验结果。 |
H
S
B
|
严格 v3 独有 | excludedprotocol_without_results | pending 0 Figure · 0 Panel · risk - |
| Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial. PMID 37311468 · Lancet · 2023-Jul-29 The trial meets criteria for oncology, human, randomized, phase 3, and drug intervention. However, the primary efficacy endpoint described is a binary response endpoint (transfusion independence with hemoglobin increase), not a time-to-event endpoint (e.g., OS, PFS). No time-to-event data or analysis (Kaplan-Meier, HR) are reported in the abstract. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Ten years of treatment with ruxolitinib for myelofibrosis: a review of safety. PMID 37501130 · J Hematol Oncol · 2023-Jul-27 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma. PMID 37272512 · N Engl J Med · 2023-Jul-27 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study. PMID 37163358 · Blood Adv · 2023-Jul-25 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 1 Figure · 1 Panel · risk visible |
| Momelotinib long-term safety and survival in myelofibrosis: integrated analysis of phase 3 randomized controlled trials. PMID 37042865 · Blood Adv · 2023-Jul-25 The record describes a pooled long-term safety and survival analysis of Phase 3 randomized trials in myelofibrosis (oncology, human, randomized, drug intervention, original result). However, the abstract explicitly states the primary focus is 'long-term safety' and 'consistent safety profile.' While 'survival' is mentioned in the title, the abstract does not report any specific time-to-event efficacy results (e.g., OS, PFS, HR, Kaplan-Meier curves). The deterministic review signal 'no_time_to_event_signal' aligns with this assessment. Therefore, it does not meet the primary criterion of a time-to-event efficacy endpoint. |
H
S
B
|
严格 v3 独有 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. PMID 37285865 · Lancet · 2023-Jul-22 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Bevacizumab in Combination With Oxaliplatin-Based Chemotherapy As First-Line Therapy in Metastatic Colorectal Cancer: A Randomized Phase III Study. PMID 37459755 · J Clin Oncol · 2023-Jul-20 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial. PMID 37290461 · Lancet · 2023-Jul-15 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | confirmed 2 Figure · 2 Panel · risk visible |
| Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3. PMID 37151113 · Cancer · 2023-Jul-15 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| A novel prostate cancer subtyping classifier based on luminal and basal phenotypes. PMID 37060201 · Cancer · 2023-Jul-15 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Plasma 25-Hydroxyvitamin D Levels and Survival in Stage III Colon Cancer: Findings from CALGB/SWOG 80702 (Alliance). PMID 37289007 · Clin Cancer Res · 2023-Jul-14 The report is an original, formal secondary analysis of a Phase III randomized trial in oncology with time-to-event endpoints. However, it fails the 'drug_intervention' criterion. The study analyzes the association of baseline plasma vitamin D levels with outcomes, not the efficacy of a drug intervention from the trial. The underlying trial (CALGB/SWOG 80702) likely involved drug treatments, but this specific report focuses on a biomarker correlation, not the primary drug efficacy results. |
H
L
S
B
|
旧组与严格 v3 交集 | excludedmodel_adjudicated_excluded | pending 0 Figure · 0 Panel · risk - |
| Overall Survival with Osimertinib in Resected EGFR-Mutated NSCLC. PMID 37272535 · N Engl J Med · 2023-Jul-13 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma. PMID 37272527 · N Engl J Med · 2023-Jul-13 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| A multicentre randomised controlled trial of a guided self-help cognitive behavioural therapy to MANage the impact of hot flushes and night sweats in patients with prostate CANcer undergoing androgen deprivation therapy (MANCAN2). PMID 37430353 · Trials · 2023-Jul-10 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
L
S
B
|
旧组与严格 v3 交集 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. PMID 36795843 · J Clin Oncol · 2023-Jul-10 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Systemic Neoadjuvant and Adjuvant Therapies in the Management of Hepatocellular Carcinoma-A Narrative Review. PMID 37444618 · Cancers (Basel) · 2023-Jul-05 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Visceral Metastasis Predicts Response to New Hormonal Agents in Metastatic Castration-Sensitive Prostate Cancer. PMID 37084289 · Oncologist · 2023-Jul-05 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Analysis of phase III clinical trials in metastatic NSCLC to assess the correlation between QoL results and survival outcomes. PMID 37400832 · BMC Med · 2023-Jul-03 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
S
B
|
严格 v3 独有 | eligiblephase3_publication_type | no_km 0 Figure · 0 Panel · risk not_applicable |
| FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study. PMID 37379692 · J Clin Oncol · 2023-Jul-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Fruquintinib versus placebo in patients with refractory metastatic colorectal cancer (FRESCO-2): an international, multicentre, randomised, double-blind, phase 3 study. PMID 37331369 · Lancet · 2023-Jul-01 命中用户提供的消化道肿瘤阳性参考集。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblepositive_reference | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Doxorubicin combined with Trabectedin in systemic first-line M+/recurrent leiomyosarcoma patients. PMID 37222199 · Curr Opin Oncol · 2023-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Adjuvant and neoadjuvant approaches in pancreatic cancer. PMID 37222189 · Curr Opin Oncol · 2023-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Efficacy and Safety of Intraoperative Hyperthermic Intraperitoneal Chemotherapy for Locally Advanced Colon Cancer: A Phase 3 Randomized Clinical Trial. PMID 37099280 · JAMA Surg · 2023-Jul-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up. PMID 37071838 · J Clin Oncol · 2023-Jul-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligibleexplicit_phase3_randomized | confirmed 1 Figure · 2 Panel · risk visible |
| Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study. PMID 37071836 · J Clin Oncol · 2023-Jul-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Kidney Adverse Events Associated with Immune Checkpoint Inhibitor Therapy: A Systematic Review and Bayesian Network Meta-Analysis. PMID 36999976 · Clin J Am Soc Nephrol · 2023-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Perioperative FLOT plus ramucirumab for resectable esophagogastric adenocarcinoma: A randomized phase II/III trial of the German AIO and Italian GOIM. PMID 36883420 · Int J Cancer · 2023-Jul-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Analysis of a Biopsy-Based Genomic Classifier in High-Risk Prostate Cancer: Meta-Analysis of the NRG Oncology/Radiation Therapy Oncology Group 9202, 9413, and 9902 Phase 3 Randomized Trials. PMID 36596347 · Int J Radiat Oncol Biol Phys · 2023-Jul-01 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Long-Term Update of NRG/RTOG 0522: A Randomized Phase 3 Trial of Concurrent Radiation and Cisplatin With or Without Cetuximab in Locoregionally Advanced Head and Neck Cancer. PMID 36549347 · Int J Radiat Oncol Biol Phys · 2023-Jul-01 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Preoperative Radiotherapy in Patients With Primary Retroperitoneal Sarcoma: EORTC-62092 Trial (STRASS) Versus Off-trial (STREXIT) Results. PMID 35833413 · Ann Surg · 2023-Jul-01 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study. PMID 37427146 · Hemasphere · 2023-Jul Explicitly identified as an international phase-3 randomized trial with drug intervention (R-CHOP) and primary/key secondary time-to-event efficacy endpoints (EFS, PFS, OS). Results are from the original trial report. |
H
S
B
|
严格 v3 独有 | eligiblemodel_adjudicated_eligible | confirmed 2 Figure · 9 Panel · risk visible |
| Radiation and Dose-densification of R-CHOP in Primary Mediastinal B-cell Lymphoma: Subgroup Analysis of the UNFOLDER Trial. PMID 37427145 · Hemasphere · 2023-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Current progress in perioperative chemotherapy for biliary tract cancer. PMID 37416744 · Ann Gastroenterol Surg · 2023-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study. PMID 37404773 · Hemasphere · 2023-Jul 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | confirmed 4 Figure · 9 Panel · risk visible |
| Real-world Efficacy and Safety of Bevacizumab for Advanced or Recurrent Müllerian Cancer: A Single-institutional Experience. PMID 37351971 · Anticancer Res · 2023-Jul 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| The evolution of immune checkpoint inhibitor combinations in advanced hepatocellular carcinoma - A systematic review. PMID 37336142 · Cancer Treat Rev · 2023-Jul 记录类型属于综述、Meta 分析、社论、评论、病例或指南。 |
H
S
B
|
严格 v3 独有 | excludedexcluded_publication_type | pending 0 Figure · 0 Panel · risk - |
| ARTISTRY-7: phase III trial of nemvaleukin alfa plus pembrolizumab vs chemotherapy for platinum-resistant ovarian cancer. PMID 37334673 · Future Oncol · 2023-Jul 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |
| First-line systemic treatment strategies in patients with initially unresectable colorectal cancer liver metastases (CAIRO5): an open-label, multicentre, randomised, controlled, phase 3 study from the Dutch Colorectal Cancer Group. PMID 37329889 · Lancet Oncol · 2023-Jul 命中用户提供的消化道肿瘤阳性参考集。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblepositive_reference | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Geriatric assessment measures are predictive of outcomes in chronic lymphocytic leukemia. PMID 37329769 · J Geriatr Oncol · 2023-Jul 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
H
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | no_km 0 Figure · 0 Panel · risk not_applicable |
| Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study. PMID 37329423 · Target Oncol · 2023-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | confirmed 1 Figure · 2 Panel · risk visible |
| Concurrent chemoradiotherapy followed by adjuvant cisplatin-gemcitabine versus cisplatin-fluorouracil chemotherapy for N2-3 nasopharyngeal carcinoma: a multicentre, open-label, randomised, controlled, phase 3 trial. PMID 37290468 · Lancet Oncol · 2023-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09-09): a randomised, open-label, multicentre, phase 3 trial. PMID 37187198 · Lancet Haematol · 2023-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Patient-reported outcomes and hospitalization data in patients with HER2-positive metastatic breast cancer receiving trastuzumab deruxtecan or trastuzumab emtansine in the phase III DESTINY-Breast03 study. PMID 37179020 · Ann Oncol · 2023-Jul 原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。 |
H
L
S
B
|
旧组与严格 v3 交集 | eligiblephase3_publication_type | needs_review 0 Figure · 0 Panel · risk not_assessed |
| Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden. PMID 37173513 · Appl Health Econ Health Policy · 2023-Jul 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。 |
H
S
B
|
严格 v3 独有 | excludedpost_hoc_or_secondary_analysis | pending 0 Figure · 0 Panel · risk - |
| Health-related quality of life with nivolumab plus relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial. PMID 37167764 · Eur J Cancer · 2023-Jul 明确的 Phase III/IIIb/II-III 随机肿瘤药物试验,且报告 time-to-event 结局。 |
S
B
|
严格 v3 独有 | eligibleexplicit_phase3_randomized | needs_review 0 Figure · 0 Panel · risk not_assessed |